ENXTAM:DSFIRChemicals
A Look At DSM-Firmenich (ENXTAM:DSFIR) Valuation As Buyback And Medisca Partnership Draw Interest
DSM-Firmenich (ENXTAM:DSFIR) has been in focus after launching a €500 million share repurchase program to cut issued capital, as well as expanding its pharmaceutical-grade vitamin API reach in the United States through Medisca.
See our latest analysis for DSM-Firmenich.
The recent dividend approval and ongoing share repurchase plan come after a period where the stock has risen around 10.5% over 90 days, but the 1-year total shareholder return is down about 28.6%. As a result, recent momentum...